KKR Launches Allyntra Engineered Solutions Platform for Medtech

Global investment firm KKR has launched Allyntra, a precision-engineered solutions platform to serve medical technology and other precision end markets.

Allyntra builds on KKR’s investment in Precipart, a foundational platform business. The New York, N.Y.-based company said it’s committing additional capital to support growth through strategic acquisitions, innovation, and commercial expansion.

Robbie Atkinson will be appointed as CEO of Allyntra and Brian Highley as chairman. Atkinson was president and CEO of Medical Manufacturing Technologies (MMT), where he led the company through significant expansion that culminated in its sale to Perimeter Solutions.

Highley boasts over three decades of experience in the medical technology industry. He was previously CEO of Cirtec, where he scaled the company from two sites into a leading provider of end-to-end services to medical technology OEMs.

Oliver Laubscher will elevate to join the Allyntra board of directors and transition from his role as CEO of Precipart.

Comments from execs

Atkinson: “The pace of innovation across medical technology and other highly engineered industries continues to accelerate. As these technologies become more sophisticated, customers are looking for partners who can help them move faster, solve increasingly complex challenges, and bring new ideas to life. That’s exactly the opportunity I see for Allyntra.”

Highley: “Throughout my career, I’ve learned that the companies that endure are the ones that combine technical excellence with a willingness to continue evolving alongside their customers. Those are the qualities I believe will define Allyntra, and I’m excited to help shape its future by working alongside Robbie and the team.”

Ali Satvat, global head of healthcare strategic growth, co-head of Americas private equity healthcare; Anuv Ratan, managing director; KKR: “Our deepened commitment to Allyntra reflects our confidence in the market opportunity and Robbie’s and Brian’s ability to bring the Allyntra vision to life. Since first investing in Precipart in 2023, we’ve become increasingly convinced of the opportunity to create a distinctive precision-engineered solutions platform. We’re pleased to continue our strategic partnership with the Laubscher family, who will remain a meaningful shareholder.”